About this item:

57 Views | 46 Downloads

Author Notes:

Address for correspondence: Anita K. McElroy, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop G14, Atlanta, GA 30329-4027, USA; email: gsz5@cdc.gov

We thank Tanya Klimova for editing the manuscript.

Subjects:

Research Funding:

This work was conducted while A.K.M. held a Burroughs Wellcome Career Award for Medical Scientists (1013362.01) and a National Institutes of Health K08 (AI119448).

Additional support was provided by the Defense Advanced Research Projects Agency (W31P4Q-14-1-0010 to A.K.M., B.S.R., G.M.L., and C.S.K.).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Immunology
  • Infectious Diseases
  • HEMORRHAGIC-FEVER
  • SERUM FERRITIN
  • IFN-ALPHA
  • INFECTION
  • PATHOGENESIS
  • DIAGNOSIS
  • CYTOKINE
  • MARBURG
  • ASSAY
  • SKIN

Macrophage Activation Marker Soluble CD163 Associated with Fatal and Severe Ebola Virus Disease in Humans

Show all authors Show less authors

Tools:

Journal Title:

Emerging Infectious Disease

Volume:

Volume 25, Number 2

Publisher:

, Pages 290-298

Type of Work:

Article | Final Publisher PDF

Abstract:

Ebola virus disease (EVD) is associated with elevated cytokine levels, and hypercytokinemia is more pronounced in fatal cases. This type of hyperinflammatory state is reminiscent of 2 rheumatologic disorders known as macrophage activation syndrome and hemophagocytic lymphohistiocytosis, which are characterized by macrophage and T-cell activation. An evaluation of 2 cohorts of patients with EVD revealed that a marker of macrophage activation (sCD163) but not T-cell activation (sCD25) was associated with severe and fatal EVD. Furthermore, substantial immunoreac-tivity of host tissues to a CD163-specific antibody, predominantly in areas of extensive immunostaining for Ebola virus antigens, was observed in fatal cases. These data suggest that host macrophage activation contributes to EVD pathogenesis and that directed antiinflammatory therapies could be beneficial in the treatment of EVD.

Copyright information:

© 2019, Centers for Disease Control and Prevention (CDC). All rights reserved.

Export to EndNote